173 related articles for article (PubMed ID: 19447172)
1. The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation.
Samuni Y; Flores-Santana W; Krishna MC; Mitchell JB; Wink DA
Free Radic Biol Med; 2009 Aug; 47(4):419-23. PubMed ID: 19447172
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide.
Samuni Y; Wink DA; Krishna MC; Mitchell JB; Goldstein S
Free Radic Biol Med; 2014 Aug; 73():291-8. PubMed ID: 24880052
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
Qiu X; Rong X; Yang J; Lu Y
BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
5. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors trichostatin A and vorinostat inhibit TGFβ2-induced lens epithelial-to-mesenchymal cell transition.
Xie L; Santhoshkumar P; Reneker LW; Sharma KK
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4731-40. PubMed ID: 24994865
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
8. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
10. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
12. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors Relax Mouse Aorta Partly through Their Inhibitory Action on L-Type Ca
Zheng C; Zhong M; Qi Z; Shen F; Zhao Q; Wu L; Huang Y; Tsang SY; Yao X
J Pharmacol Exp Ther; 2017 Nov; 363(2):211-220. PubMed ID: 28860353
[TBL] [Abstract][Full Text] [Related]
14. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
16. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
17. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).
Henderson C; Mizzau M; Paroni G; Maestro R; Schneider C; Brancolini C
J Biol Chem; 2003 Apr; 278(14):12579-89. PubMed ID: 12556448
[TBL] [Abstract][Full Text] [Related]
18. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.
Zhu Z; Jiang W; McGinley JN; Thompson HJ
Cancer Prev Res (Phila); 2013 Apr; 6(4):290-8. PubMed ID: 23365133
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
